Table 3.

Clinical trials using LPA signaling as a therapeutic target for different pathologies^a

Study	ClinicalTrials.gov Identifier	Sponsor	Disease	Phase	Drug inhibitor
Safety and efficacy of a LPA receptor antagonist in idiopathic pulmonary fibrosis	NCT01766817	Bristol-Myers Squibb	Idiopathic pulmonary fibrosis	2	LPAR1 inhibitor drug: BMS-986020
Safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT-877 in healthy subjects	NCT03830125	Bridge Biotherapeutics, Inc.	Idiopathic pulmonary fibrosis	1	ATX inhibitor
Phase 2a, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation	NCT02690519	Galapagos NV	Cystic fibrosis	2	ATX inhibitor
Phase 2a, open-label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation	NCT02707562	Galapagos NV	Cystic fibrosis	2	ATX inhibitor
Evaluation of the pharmacokinetics, safety and tolerability of a single dose of GLPG3067 administered as solid formulation in male subjects with cystic fibrosis	NCT03589313	Galapagos NV	Cystic fibrosis	1	ATX inhibitor
Evaluation of the pharmacokinetics, safety and tolerability of a single dose of GLPG2737 administered as oral suspension in male subjects with cystic fibrosis	NCT03450720	Galapagos NV	Cystic fibrosis	1	ATX inhibitor
Phase 2a, randomized, double-blinded placebo-controlled study to evaluate GLPG2737 in orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation	NCT03474042	Galapagos NV	Cystic fibrosis	2	ATX inhibitor
Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with cystic fibrosis harboring one F508del CFTR mutation and a second gating (Class III) mutation	NCT03045523	Galapagos NV	Cystic fibrosis	2	ATX inhibitor
Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosis	NCT03540524	Galapagos NV	Cystic fibrosis	1	ATX inhibitor
Phase 2a, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with cystic fibrosis who are homozygous for the F508del mutation	NCT03119649	Galapagos NV	Cystic fibrosis	2	ATX inhibitor
Phase 2 randomized, double-blinded, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis	NCT03725852	Galapagos NV	Idiopathic pulmonary fibrosis	2	ATX inhibitor
Phase 3, randomized, double-blinded, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis	NCT03733444	Galapagos NV	Idiopathic pulmonary fibrosis	3	ATX inhibitor
Phase 3, randomized, double-blinded, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis	NCT03711162	Galapagos NV	Idiopathic pulmonary fibrosis	3	ATX inhibitor
Randomized, double-blind, parallel group, placebo-controlled, multicenter, exploratory phase 2a study to assess safety, tolerability, pharmacokinetic and pharmacodynamic properties of GLPG1690 administered for 12 weeks in subjects with idiopathic pulmonary fibrosis (IPF)	NCT02738801	Galapagos NV	Idiopathic pulmonary fibrosis	2	ATX inhibitor
Double-blinded, randomized, 8-week placebo-controlled, and 16-week open-label extension study investigating the safety, pharmacokinetics and pharmacodynamics of SAR100842 given orally to patients with diffuse cutaneous systemic sclerosis	NCT01651143	Sanofi	Systemic sclerosis	2	LPAR1 inhibitor SAR100842

^aData extracted from www.clinicaltrials.gov